3. Schneider I, Thumfart WF, Pototschnig C, Eckel HE. Treatment of dysfunction of the cricopharyngeal muscle with botulinum A toxin: introduction of a new, noninvasive method. Ann Otol Rhinol Laryngol. 1994 Jan;103(1):31-5.
4. Nasri S, Sercarz JA, McAlpin T, Berke GS. Treatment of vocal fold granuloma using botulinum toxin type A. Laryngoscope. 1995 Jun;105(6):585-8.
5. Drobik C, Laskawi R. Frey’s syndrome: treatment with botulinum toxin. Acta Otolaryngol. 1995 May;115(3):459-61.
8. Vargas H, Galati LT, Parnes SM. A pilot study evaluating the treatment of postparotidectomy sialoceles with botulinum toxin type A. Arch Otolaryngol Head Neck Surg. 2000 Mar;126(3):421-4.
10. Ali MJ, Orloff LA, Lustig LR, Eisele DW. Botulinum toxin in the treatment of first bite syndrome. Otolaryngol Head Neck Surg. 2008 Nov;139(5):742-3.
11. Lee BJ, Lee JC, Lee YO, Wang SG, Kim HJ. Novel treatment of first bite syndrome using botulinum toxin type A. Head Neck. 2009 Aug;31(8):989-93.
12. Chiu SY, Burns MR, Malaty IA. An update on botulinum toxin in neurology. Neurol Clin. 2021 Feb;39(1):209-29.
14. Jankovic J. Botulinum toxin: state of the art. Mov Disord. 2017 Aug;32(8):1131-8.
15. Smith TJ, Hill KK, Raphael BH. Historical and current perspectives on Clostridium botulinum diversity. Res Microbiol. 2015 May;166(4):290-302.
17. Qerama E, Fuglsang-Frederiksen A, Jensen TS. The role of botulinum toxin in management of pain: an evidence-based review. Curr Opin Anaesthesiol. 2010 Oct;23(5):602-10.
18. Kim JE, Song EJ, Choi GS, Lew BL, Sim WY, Kang H. The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plast Reconstr Surg. 2015 Mar;135(3):732-41.
19. Cha W, Jang JY, Wang SG, Kang JH, Jo MG. Liquid-type botulinum toxin type A in adductor spasmodic dysphonia: a prospective pilot study. J Voice. 2017 May;31(3):378.
20. Scaglione F. Conversion ratio between Botox(R), Dysport(R), and Xeomin(R) in clinical practice. Toxins (Basel). 2016 Mar;8(3):65.
21. Ministry of Food and Drug Safety (KR). Notification of change of permission according to drug re-examination results [Allergan Korea, 50 units of Botox (Clostridium botulinum toxin type A)] [Internet]. Ministry of Food and Drug Safety; 2018 [cited 2023 Oct 31]. Available from:
https://nedrug.mfds.go.kr/bbs/58/3137/#.
22. Cote TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005 Sep;53(3):407-15.
23. Lee SW. Botulinum toxin for other head and neck lesions. J Korean Soc Laryngol Phoniatr Logop. 2012;23(2):104-10.
25. Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 2013 Apr;66(4):408-14.
27. Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope. 1998 Oct;108(10):1435-41.
28. Watts C, Nye C, Whurr R. Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): a systematic Cochrane review. Clin Rehabil. 2006 Feb;20(2):112-22.
29. Boutsen F, Cannito MP, Taylor M, Bender B. Botox treatment in adductor spasmodic dysphonia: a meta-analysis. J Speech Lang Hear Res. 2002 Jun;45(3):469-81.
30. Troung DD, Rontal M, Rolnick M, Aronson AE, Mistura K. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope. 1991 Jun;101(6 Pt 1):630-4.
31. Hyodo M, Nagao A, Asano K, Sakaguchi M, Mizoguchi K, Omori K, et al. Botulinum toxin injection into the intrinsic laryngeal muscles to treat spasmodic dysphonia: a multicenter, placebo-controlled, randomized, double-blinded, parallel-group comparison/open-label clinical trial. Eur J Neurol. 2021 May;28(5):1548-56.
32. Faham M, Ahmadi A, Silverman E, Harouni GG, Dabirmoghaddam P. Quality of life after botulinum toxin injection in patients with adductor spasmodic dysphonia; a systematic review and meta-analysis. J Voice. 2021 Mar;35(2):271-83.
33. Courey MS, Garrett CG, Billante CR, Stone RE, Portell MD, Smith TL, et al. Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin. Ann Otol Rhinol Laryngol. 2000 Sep;109(9):819-22.
34. van Esch BF, Wegner I, Stegeman I, Grolman W. Effect of botulinum toxin and surgery among spasmodic dysphonia patients. Otolaryngol Head Neck Surg. 2017 Feb;156(2):238-54.
35. Dharia I, Bielamowicz S. Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia in a large cohort. Laryngoscope. 2020 Nov;130(11):2659-62.
36. Adams SG, Hunt EJ, Irish JC, Charles DA, Lang AE, Durkin LC, et al. Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia. J Otolaryngol. 1995 Dec;24(6):345-51.
37. Lee SJ, Kang MS, Choi HS, Lim JY. Alternating unilateral versus bilateral injections of botulinum toxin for the treatment of adductor spasmodic dysphonia. Otolaryngol Head Neck Surg. 2021 Apr;164(4):815-20.
39. Bielamowicz S, Stager SV, Badillo A, Godlewski A. Unilateral versus bilateral injections of botulinum toxin in patients with adductor spasmodic dysphonia. J Voice. 2002 Mar;16(1):117-23.
40. Langeveld TP, Drost HA, Baatenburg de Jong RJ. Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol. 1998 Apr;107(4):280-4.
41. Koriwchak MJ, Netterville JL, Snowden T, Courey M, Ossoff RH. Alternating unilateral botulinum toxin type A (BOTOX) injections for spasmodic dysphonia. Laryngoscope. 1996 Dec;106(12 Pt 1):1476-81.
44. Rosow DE, Parikh P, Vivero RJ, Casiano RR, Lundy DS. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia. Otolaryngol Head Neck Surg. 2013 Jun;148(6):1003-6.
45. Novakovic D, Waters HH, D’Elia JB, Blitzer A. Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes. Laryngoscope. 2011 Mar;121(3):606-12.
46. Bielamowicz S, Squire S, Bidus K, Ludlow CL. Assessment of posterior cricoarytenoid botulinum toxin injections in patients with abductor spasmodic dysphonia. Ann Otol Rhinol Laryngol. 2001 May;110(5 Pt 1):406-12.
47. Woodson G, Hochstetler H, Murry T. Botulinum toxin therapy for abductor spasmodic dysphonia. J Voice. 2006 Mar;20(1):137-43.
48. Klein AM, Stong BC, Wise J, DelGaudio JM, Hapner ER, Johns MM 3rd. Vocal outcome measures after bilateral posterior cricoarytenoid muscle botulinum toxin injections for abductor spasmodic dysphonia. Otolaryngol Head Neck Surg. 2008 Sep;139(3):421-3.
49. Bhatia KP, Bain P, Bajaj N, Elble RJ, Hallett M, Louis ED, et al. Consensus statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord. 2018 Jan;33(1):75-87.
50. Haubenberger D, Hallett M. Essential tremor. N Engl J Med. 2018 May;378(19):1802-10.
51. Sulica L, Louis ED. Clinical characteristics of essential voice tremor: a study of 34 cases. Laryngoscope. 2010 Mar;120(3):516-28.
53. Sharma S, Pandey S. Treatment of essential tremor: current status. Postgrad Med J. 2020 Feb;96(1132):84-93.
54. Hertegard S, Granqvist S, Lindestad PA. Botulinum toxin injections for essential voice tremor. Ann Otol Rhinol Laryngol. 2000 Feb;109(2):204-9.
56. Adler CH, Bansberg SF, Hentz JG, Ramig LO, Buder EH, Witt K, et al. Botulinum toxin type A for treating voice tremor. Arch Neurol. 2004 Sep;61(9):1416-20.
57. Gurey LE, Sinclair CF, Blitzer A. A new paradigm for the management of essential vocal tremor with botulinum toxin. Laryngoscope. 2013 Oct;123(10):2497-501.
58. Orbelo DM, Duffy JR, Hughes Borst BJ, Ekbom D, Maragos NE. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor. J Voice. 2014 Jan;28(1):123-7.
59. Benninger MS, Smith LJ. Noncosmetic uses of botulinum toxin in otolaryngology. Cleve Clin J Med. 2015 Nov;82(11):729-32.
60. Hoffman HT, Overholt E, Karnell M, McCulloch TM. Vocal process granuloma. Head Neck. 2001 Dec;23(12):1061-74.
62. Shoffel-Havakuk H, Sadoughi B, Sulica L, Johns MM 3rd. In-office procedures for the treatment of benign vocal fold lesions in the awake patient: a contemporary review. Laryngoscope. 2019 Sep;129(9):2131-8.
63. Rudman JR, McGee CS, Diaz J, Rosow DE. Assessing the utility of non-surgical treatments in the management of vocal process granulomas. J Laryngol Otol. 2020 Jan;134(1):68-73.
64. Karkos PD, George M, Van Der Veen J, Atkinson H, Dwivedi RC, Kim D, et al. Vocal process granulomas: a systematic review of treatment. Ann Otol Rhinol Laryngol. 2014 May;123(5):314-20.
65. Yilmaz T, Kayahan B, Gunaydin RO, Kuscu O, Sozen T. Botulinum toxin a for treatment of contact granuloma. J Voice. 2016 Nov;30(6):741-3.
66. Pham Q, Campbell R, Mattioni J, Sataloff R. Botulinum toxin injections into the lateral cricoarytenoid muscles for vocal process granuloma. J Voice. 2018 May;32(3):363-6.
67. Hamdan AL, Khalifee E, Jaffal H, Ghanem A. Interarytenoid botulinum toxin A injection for the treatment of vocal process granuloma. J Laryngol Otol. 2019 Dec;133(12):1041-5.
68. Fink DS, Achkar J, Franco RA, Song PC. Interarytenoid botulinum toxin injection for recalcitrant vocal process granuloma. Laryngoscope. 2013 Dec;123(12):3084-7.
69. Orloff LA, Goldman SN. Vocal fold granuloma: successful treatment with botulinum toxin. Otolaryngol Head Neck Surg. 1999 Oct;121(4):410-3.
70. Pham J, Yin S, Morgan M, Stucker F, Nathan CO. Botulinum toxin: helpful adjunct to early resolution of laryngeal granulomas. J Laryngol Otol. 2004 Oct;118(10):781-5.
71. Ho CF, Lee YC, Hsin LJ, Lee LA, Li HY, Fang TJ. Low-dose LEMGguided botulinum toxin type A injection for intractable vocal process granulomas. J Voice. 2022 Mar;36(2):277-82.
72. Lei L, Yang H, Zhang X, Ren J. Comparison of the effects of esomeprazole plus mosapride citrate and botulinum toxin A on vocal process granuloma. Am J Otolaryngol. 2017 Sep-Oct;38(5):593-97.
73. Lee SW, Hong HJ, Choi SH, Sun DI, Park YH, Lee BJ, et al. Comparison of treatment modalities for contact granuloma: a nationwide multicenter study. Laryngoscope. 2014 May;124(5):1187-91.
74. Damrose EJ, Damrose JF. Botulinum toxin as adjunctive therapy in refractory laryngeal granuloma. J Laryngol Otol. 2008 Aug;122(8):824-8.
75. Yilmaz T, Suslu N, Atay G, Ozer S, Gunaydin RO, Bajin MD. Recurrent contact granuloma: experience with excision and botulinum toxin injection. JAMA Otolaryngol Head Neck Surg. 2013 Jun;139(6):579-83.
76. Ma L, Xiao Y, Ye J, Yang Q, Wang J. Analysis of therapeutic methods for treating vocal process granulomas. Acta Otolaryngol. 2015 Mar;135(3):277-82.
77. Kraimer KL, Husain I. Updated medical and surgical treatment for common benign laryngeal lesions. Otolaryngol Clin North Am. 2019 Aug;52(4):745-57.
78. Czesak MA, Osuch-Wojcikiewicz E, Niemczyk K. Methods of surgical treatment of bilateral vocal fold paralysis. Endokrynol Pol. 2020;71(4):350-8.
80. Ongkasuwan J, Courey M. The role of botulinum toxin in the management of airway compromise due to bilateral vocal fold paralysis. Curr Opin Otolaryngol Head Neck Surg. 2011 Dec;19(6):444-8.
81. Ekbom DC, Garrett CG, Yung KC, Johnson FL, Billante CR, Zealear DL, et al. Botulinum toxin injections for new onset bilateral vocal fold motion impairment in adults. Laryngoscope. 2010 Apr;120(4):758-63.
82. Zealear DL, Billante CR, Courey MS, Sant’Anna GD, Netterville JL. Electrically stimulated glottal opening combined with adductor muscle Botox blockade restores both ventilation and voice in a patient with bilateral laryngeal paralysis. Ann Otol Rhinol Laryngol. 2002 Jun;111(6):500-6.
83. Marchese MR, Bussu F, Settimi S, Scarano E, Almadori G, Galli J. Not only gustatory sweating and flushing: signs and symptoms associated to the Frey syndrome and the role of botulinum toxin A therapy. Head Neck. 2021 Mar;43(3):949-55.
84. Baek CH, Chung MK, Jeong HS, Son YI, Jung SC, Jeon HK, et al. Questionnaire evaluation of sequelae over 5 years after parotidectomy for benign diseases. J Plast Reconstr Aesthet Surg. 2009 May;62(5):633-8.
85. Neumann A, Rosenberger D, Vorsprach O, Dazert S. The incidence of Frey syndrome following parotidectomy: results of a survey and follow-up. HNO. 2011 Feb;59(2):173-8.
86. Vahtsevanos K, Chatziavramidis A, Papadiochos IY, Koloutsos G, Stefanidis A, Kitikidou K, et al. Prevention of Frey’s syndrome with the use of porcine dermal collagen graft: retrospective analysis of 76 “formal” parotidectomies for benign pathologies. Ann Otol Rhinol Laryngol. 2021 Sep;130(9):1036-43.
87. Eckardt A, Kuettner C. Treatment of gustatory sweating (Frey’s syndrome) with botulinum toxin A. Head Neck. 2003 Aug;25(8):624-8.
88. De Virgilio A, Costantino A, Russo E, Ferreli F, Pellini R, Petruzzi G, et al. Different surgical strategies in the prevention of Frey syndrome: a systematic review and meta-analysis. Laryngoscope. 2021 Aug;131(8):1761-8.
89. Li C, Yang X, Pan J, Shi Z, Li L. Graft for prevention of Frey syndrome after parotidectomy: a systematic review and meta-analysis of randomized controlled trials. J Oral Maxillofac Surg. 2013 Feb;71(2):419-27.
90. Sanabria A, Kowalski LP, Bradley PJ, Hartl DM, Bradford CR, de Bree R, et al. Sternocleidomastoid muscle flap in preventing Frey’s syndrome after parotidectomy: a systematic review. Head Neck. 2012 Apr;34(4):589-98.
91. Hays LL. The Frey syndrome: a review and double blind evaluation of the topical use of a new anticholinergic agent. Laryngoscope. 1978 Nov;88(11):1796-824.
92. de Bree R, van der Waal I, Leemans CR. Management of Frey syndrome. Head Neck. 2007 Aug;29(8):773-8.
93. Jansen S, Jerowski M, Ludwig L, Fischer-Krall E, Beutner D, Grosheva M. Botulinum toxin therapy in Frey’s syndrome: a retrospective study of 440 treatments in 100 patients. Clin Otolaryngol. 2017 Apr;42(2):295-300.
94. Laccourreye O, Muscatelo L, Naude C, Bonan B, Brasnu D. Botulinum toxin type A for Frey’s syndrome: a preliminary prospective study. Ann Otol Rhinol Laryngol. 1998 Jan;107(1):52-5.
95. Naumann M, Zellner M, Toyka KV, Reiners K. Treatment of gustatory sweating with botulinum toxin. Ann Neurol. 1997 Dec;42(6):973-5.
96. Laccourreye O, Akl E, Gutierrez-Fonseca R, Garcia D, Brasnu D, Bonan B. Recurrent gustatory sweating (Frey syndrome) after intracutaneous injection of botulinum toxin type A: incidence, management, and outcome. Arch Otolaryngol Head Neck Surg. 1999 Mar;125(3):283-6.
97. de Bree R, Duyndam JE, Kuik DJ, Leemans CR. Repeated botulinum toxin type A injections to treat patients with Frey syndrome. Arch Otolaryngol Head Neck Surg. 2009 Mar;135(3):287-90.
98. Beerens AJ, Snow GB. Botulinum toxin A in the treatment of patients with Frey syndrome. Br J Surg. 2002 Jan;89(1):116-9.
100. Hartl DM, Julieron M, LeRidant AM, Janot F, Marandas P, Travagli JP. Botulinum toxin A for quality of life improvement in post-parotidectomy gustatory sweating (Frey’s syndrome). J Laryngol Otol. 2008 Oct;122(10):1100-4.
102. Lee YC, Park GC, Lee JW, Eun YG, Kim SW. Prevalence and risk factors of sialocele formation after partial superficial parotidectomy: a multi-institutional analysis of 357 consecutive patients. Head Neck. 2016 Apr;38 Suppl 1:E941-4.
103. Marchese-Ragona R, Marioni G, Restivo DA, Staffieri A. The role of botulinum toxin in postparotidectomy fistula treatment: a technical note. Am J Otolaryngol. 2006 May-Jun;27(3):221-4.
104. Costan VV, Dabija MG, Ciofu ML, Sulea D, Popescu E, Boisteanu O. A functional approach to posttraumatic salivary fistula treatment: the use of botulinum toxin. J Craniofac Surg. 2019 May/Jun;30(3):871-5.
105. Melville JC, Stackowicz DJ, Jundt JS, Shum JW. Use of Botox (OnabotulinumtoxinA) for the treatment of parotid sialocele and fistula after extirpation of buccal squamous cell carcinoma with immediate reconstruction using microvascular free flap: a report of 3 cases. J Oral Maxillofac Surg. 2016 Aug;74(8):1678-86.
106. Lee DJ, Lee YM, Park HJ, Lee JW, Cha W. Intraoperative botulinum toxin injection for superficial partial parotidectomy: a prospective pilot study. Clin Otolaryngol. 2021 Sep;46(5):998-1004.
107. Laskawi R, Winterhoff J, Kohler S, Kottwitz L, Matthias C. Botulinum toxin treatment of salivary fistulas following parotidectomy: follow-up results. Oral Maxillofac Surg. 2013 Dec;17(4):281-5.
108. Send T, Bertlich M, Eichhorn KW, Bootz F, Jakob M. management and follow-up results of salivary fistulas treated with botulinum toxin. Laryngoscope. 2019 Feb;129(2):403-8.
110. Varley LP, Denieffe S, O’Gorman C, Murphy A, Gooney M. A systematic review of noninvasive and invasive sialorrhoea management. J Clin Nurs. 2019 Dec;28(23-24):4190-206.
111. Vashishta R, Nguyen SA, White DR, Gillespie MB. Botulinum toxin for the treatment of sialorrhea: a meta-analysis. Otolaryngol Head Neck Surg. 2013 Feb;148(2):191-6.
112. Wu KP, Ke JY, Chen CY, Chen CL, Chou MY, Pei YC. Botulinum toxin type A on oral health in treating sialorrhea in children with cerebral palsy: a randomized, double-blind, placebo-controlled study. J Child Neurol. 2011 Jul;26(7):838-43.
115. Jackson CE, Gronseth G, Rosenfeld J, Barohn RJ, Dubinsky R, Simpson CB, et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve. 2009 Feb;39(2):137-43.
116. Hughes A, Choi S. Does intraglandular injection of botulinum toxin improve pediatric sialorrhea. Laryngoscope. 2018 Jul;128(7):1513-4.
117. Van der Burg JJ, Jongerius PH, Van Hulst K, Van Limbeek J, Rotteveel JJ. Drooling in children with cerebral palsy: effect of salivary flow reduction on daily life and care. Dev Med Child Neurol. 2006 Feb;48(2):103-7.
118. Naumann M, Dressler D, Hallett M, Jankovic J, Schiavo G, Segal KR, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon. 2013 Jun;67:141-52.
119. Gonzalez-L MD, Martinez C, Bori Y Fortuny I, Suso-Vergara S. Factors in the efficacy, safety, and impact on quality of life for treatment of drooling with botulinum toxin type A in patients with cerebral palsy. Am J Phys Med Rehabil. 2017 Feb;96(2):68-76.
120. Jost WH, Friedman A, Michel O, Oehlwein C, Slawek J, Bogucki A, et al. Long-term incobotulinumtoxinA treatment for chronic sialorrhea: efficacy and safety over 64 weeks. Parkinsonism Relat Disord. 2020 Jan;70:23-30.
121. Bekkers S, Delsing CP, Kok SE, van Hulst K, Erasmus CE, Scheffer AR, et al. Randomized controlled trial comparing botulinum vs surgery for drooling in neurodisabilities. Neurology. 2019 Mar;92(11):e1195-204.
122. Lungren MP, Halula S, Coyne S, Sidell D, Racadio JM, Patel MN. Ultrasound-guided botulinum toxin type A salivary gland injection in children for refractory sialorrhea: 10-year experience at a large tertiary children’s hospital. Pediatr Neurol. 2016 Jan;54:70-5.
123. Chinnapongse R, Gullo K, Nemeth P, Zhang Y, Griggs L. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson’s disease: a prospective double-blind trial. Mov Disord. 2012 Feb;27(2):219-26.
126. Shehee L, O’Rourke A, Garand KL. The role of radiation therapy and botulinum toxin injections in the management of sialorrhea in patients with amyotrophic lateral sclerosis: a systematic review. J Clin Neuromuscul Dis. 2020 Jun;21(4):205-21.
127. Squires N, Humberstone M, Wills A, Arthur A. The use of botulinum toxin injections to manage drooling in amyotrophic lateral sclerosis/motor neurone disease: a systematic review. Dysphagia. 2014 Aug;29(4):500-8.
129. Abdel Jalil AA, Katzka DA, Castell DO. Approach to the patient with dysphagia. Am J Med. 2015 Oct;128(10):1138.
130. Cook IJ, Kahrilas PJ. AGA technical review on management of oropharyngeal dysphagia. Gastroenterology. 1999 Feb;116(2):455-78.
131. Kuhn MA, Belafsky PC. Management of cricopharyngeus muscle dysfunction. Otolaryngol Clin North Am. 2013 Dec;46(6):1087-99.
132. Martino R, McCulloch T. Therapeutic intervention in oropharyngeal dysphagia. Nat Rev Gastroenterol Hepatol. 2016 Nov;13(11):665-79.
133. Dewan K, Santa Maria C, Noel J. Cricopharyngeal achalasia: management and associated outcomes-a scoping review. Otolaryngol Head Neck Surg. 2020 Dec;163(6):1109-13.
134. Lee SY, Seo HG, Paik NJ. Botulinum toxin injection for dysphagia: a blinded retrospective videofluoroscopic swallowing study analysis. Am J Phys Med Rehabil. 2009 Jun;88(6):491-4.
135. Chavez YH, Ciarleglio MM, Clarke JO, Nandwani M, Stein E, Roland BC. Upper esophageal sphincter abnormalities: frequent finding on high-resolution esophageal manometry and associated with poorer treatment response in achalasia. J Clin Gastroenterol. 2015 Jan;49(1):17-23.
136. Moerman MB. Cricopharyngeal Botox injection: indications and technique. Curr Opin Otolaryngol Head Neck Surg. 2006 Dec;14(6):431-6.
137. Blitzer A, Brin MF. Use of botulinum toxin for diagnosis and management of cricopharyngeal achalasia. Otolaryngol Head Neck Surg. 1997 Mar;116(3):328-30.
138. Ahsan SF, Meleca RJ, Dworkin JP. Botulinum toxin injection of the cricopharyngeus muscle for the treatment of dysphagia. Otolaryngol Head Neck Surg. 2000 May;122(5):691-5.
139. Alberty J, Oelerich M, Ludwig K, Hartmann S, Stoll W. Efficacy of botulinum toxin A for treatment of upper esophageal sphincter dysfunction. Laryngoscope. 2000 Jul;110(7):1151-6.
140. Haapaniemi JJ, Laurikainen EA, Pulkkinen J, Marttila RJ. Botulinum toxin in the treatment of cricopharyngeal dysphagia. Dysphagia. 2001 Summer;16(3):171-5.
141. Shaw GY, Searl JP. Botulinum toxin treatment for cricopharyngeal dysfunction. Dysphagia. 2001 Summer;16(3):161-7.
142. Parameswaran MS, Soliman AM. Endoscopic botulinum toxin injection for cricopharyngeal dysphagia. Ann Otol Rhinol Laryngol. 2002 Oct;111(10):871-4.
143. Chao SS, Graham SM, Hoffman HT. Management of pharyngoesophageal spasm with Botox. Otolaryngol Clin North Am. 2004 Jun;37(3):559-66.
144. Zaninotto G, Marchese Ragona R, Briani C, Costantini M, Rizzetto C, Portale G, et al. The role of botulinum toxin injection and upper esophageal sphincter myotomy in treating oropharyngeal dysphagia. J Gastrointest Surg. 2004 Dec;8(8):997-1006.
145. Murry T, Wasserman T, Carrau RL, Castillo B. Injection of botulinum toxin A for the treatment of dysfunction of the upper esophageal sphincter. Am J Otolaryngol. 2005 May-Jun;26(3):157-62.
148. Kocdor P, Siegel ER, Tulunay-Ugur OE. Cricopharyngeal dysfunction: a systematic review comparing outcomes of dilatation, botulinum toxin injection, and myotomy. Laryngoscope. 2016 Jan;126(1):135-41.
149. Miles A, Allen JE. Management of oropharyngeal neurogenic dysphagia in adults. Curr Opin Otolaryngol Head Neck Surg. 2015 Dec;23(6):433-9.
150. Terre R, Panades A, Mearin F. Botulinum toxin treatment for oropharyngeal dysphagia in patients with stroke. Neurogastroenterol Motil. 2013 Nov;25(11):896-e702.
151. Restivo DA, Marchese-Ragona R, Patti F, Solaro C, Maimone D, Zappala G, et al. Botulinum toxin improves dysphagia associated with multiple sclerosis. Eur J Neurol. 2011 Mar;18(3):486-90.
152. Restivo DA, Marchese-Ragona R, Lauria G, Squatrito S, Gullo D, Vigneri R. Botulinum toxin treatment for oropharyngeal dysphagia associated with diabetic neuropathy. Diabetes Care. 2006 Dec;29(12):2650-3.
153. Kim DY, Park CI, Ohn SH, Moon JY, Chang WH, Park SW. Botulinum toxin type A for poststroke cricopharyngeal muscle dysfunction. Arch Phys Med Rehabil. 2006 Oct;87(10):1346-51.
154. Abu-Ghanem S, Sung CK, Junlapan A, Kearney A, DiRenzo E, Dewan K, et al. Endoscopic management of postradiation dysphagia in head and neck cancer patients: a systematic review. Ann Otol Rhinol Laryngol. 2019 Aug;128(8):767-73.
155. Jeong SH, Kim YJ, Kim YJ, Park KD, Kim EJ, Chung JW, et al. Endoscopic botulinum toxin injection for treatment of pharyngeal dysphagia in patients with cricopharyngeal dysfunction. Scand J Gastroenterol. 2018 Oct-Nov;53(10-11):1201-5.
156. Xie M, Zeng P, Wan G, An D, Tang Z, Li C, et al. The effect of combined guidance of botulinum toxin injection with ultrasound, catheter balloon, and electromyography on neurogenic cricopharyngeal dysfunction: a prospective study. Dysphagia. 2022 Jun;37(3):601-11.
157. Kim MS, Kim GW, Rho YS, Kwon KH, Chung EJ. Office-based electromyography-guided botulinum toxin injection to the cricopharyngeus muscle: optimal patient selection and technique. Ann Otol Rhinol Laryngol. 2017 May;126(5):349-56.
158. Huai J, Hou Y, Guan J, Zhang Y, Wang Y, Zhang X, et al. Botulinum toxin A injection using esophageal balloon radiography combined with CT guidance for the treatment of cricopharyngeal dysphagia. Dysphagia. 2020 Aug;35(4):630-5.
159. Sharma SD, Kumar G, Eweiss A, Chatrath P, Kaddour H. Endoscopic-guided injection of botulinum toxin into the cricopharyngeus muscle: our experience. J Laryngol Otol. 2015 Oct;129(10):990-5.
160. Kim MJ, Min YW. Endoscopic management of dysphagia. Korean J Gastroenterol. 2021 Feb;77(2):77-83.
161. Woisard-Bassols V, Alshehri S, Simonetta-Moreau M. The effects of botulinum toxin injections into the cricopharyngeus muscle of patients with cricopharyngeus dysfunction associated with pharyngolaryngeal weakness. Eur Arch Otorhinolaryngol. 2013 Mar;270(3):805-15.
162. Ashman A, Dale OT, Baldwin DL. Management of isolated cricopharyngeal dysfunction: systematic review. J Laryngol Otol. 2016 Jul;130(7):611-5.
163. Kwon SY, Chun KJ, Kil HK, Oh KH, Kim C, Jang SJ, et al. Botulinum toxin injection for chronic parotitis: a multi-center and prospective trial. Laryngoscope. 2021 Jun;131(6):E1903-9.
164. Capaccio P, Torretta S, Osio M, Minorati D, Ottaviani F, Sambataro G, et al. Botulinum toxin therapy: a tempting tool in the management of salivary secretory disorders. Am J Otolaryngol. 2008 SepOct;29(5):333-8.
165. Netterville JL, Jackson CG, Miller FR, Wanamaker JR, Glasscock ME. Vagal paraganglioma: a review of 46 patients treated during a 20-year period. Arch Otolaryngol Head Neck Surg. 1998 Oct;124(10):1133-40.
166. Cohen SM, Burkey BB, Netterville JL. Surgical management of parapharyngeal space masses. Head Neck. 2005 Aug;27(8):669-75.
167. Deganello A, Meccariello G, Busoni M, Franchi A, Gallo O. First bite syndrome as presenting symptom of parapharyngeal adenoid cystic carcinoma. J Laryngol Otol. 2011 Apr;125(4):428-31.
168. Diercks GR, Rosow DE, Prasad M, Kuhel WI. A case of preoperative “first-bite syndrome” associated with mucoepidermoid carcinoma of the parotid gland. Laryngoscope. 2011 Apr;121(4):760-2.
169. Costales-Marcos M, Lopez Alvarez F, Fernandez-Vanes L, Gomez J, Llorente JL. Treatment of the first bite syndrome. Acta Otorrinolaringol Esp (Engl Ed). 2017 Sep-Oct;68(5):284-8.
170. Ghosh A, Mirza N. First bite syndrome: our experience with intraparotid injections with botulinum toxin type A. Laryngoscope. 2016 Jan;126(1):104-7.
171. Sims JR, Suen JY. First bite syndrome: case report of 3 patients treated with botulinum toxin and review of other treatment modalities. Head Neck. 2013 Sep;35(9):E288-91.
172. Laccourreye O, Werner A, Garcia D, Malinvaud D, Tran Ba Huy P, Bonfils P. First bite syndrome. Eur Ann Otorhinolaryngol Head Neck Dis. 2013 Nov;130(5):269-73.
174. Steel SJ, Robertson CE. First bite syndrome: what neurologists need to know. Curr Pain Headache Rep. 2021 Mar;25(5):31.
175. Amin N, Pelser A, Weighill J. First bite syndrome: our experience of laser tympanic plexus ablation. J Laryngol Otol. 2014 Feb;128(2):166-8.